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Hepatic inflammation is the stimulator to activate hepatic stellate cells (HSCs) and triggers 
fibrogenesis. Cytokines are produced during liver inflammation and maybe considered as liver fibrosis 
biomarker. The aim of this study was to investigate whether cytokines can be used as reliable 
biomarkers of liver fibrosis using flexible multi-analyte profiling (xMAP). A total of 61 chronic hepatitis C 
patients with different severity of liver fibrosis were enrolled. Liver biopsy was used as standard to 
assess the severity of fibrosis according to METAVIR classification. Afterward, 15 samples from healthy 
controls were analyzed and totally 50 cytokines were screened using flexible multi-analyte profiling to 
discover differential biomarkers. Finally, levels of protein expressions of individual stages of liver 
fibrosis were measured. In histological examination, the necroinflammatory score (histology activity 
index, HAI) was increased from F1 to F4 stage in hepatitis C virus (HCV) infected patients, indicating that 
inflammation was accompanied with the progression of liver fibrosis. Using flexible multi-analyte 
profiling, four serum cytokines, including IFN-α2 (p=0.023), GRO-α (p=0.013), SCF (p=0.047) and SDF-1α 
(p=0.024), were identified under antibody specific recognition and elevated with HAI score. This study 
reveals the relationship between cytokines and liver fibrosis, and demonstrated that IFN-α2, GRO-α, 
SCF and SDF-1α may be used as biomarkers to predict liver fibrosis. The overexpressed cytokines may 
play a role in the progression of liver fibrosis and deserves further investigation. 
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grade  the  severity  of  liver  disease  in  clinical  practice. 
Although liver biopsy followed by histological examination 
is still the gold standard to diagnose liver fibrosis (Afdhal 
and Nunes, 2004), it is necessary to  develop some other 
methods to improve diagnostic accuracy and reduce the 
disadvantages of biopsy such as invasive  character  and 
small sample size (Regev et al., 2002; 
Thampanitchawong and   Piratvisuth, 1999).   Nowadays, 




noninvasive diagnostic techniques such as ultra-
sonography,    computed    tomography    and    magnetic  
resonance imaging have been used to detect the 
morphological changes in the hepatic parenchyma for 
advanced fibrosis (Hirata et al., 2001). As a reliable 
predictor, FibroScan has been used recently to diagnose 
liver fibrosis (Zhu et al., 2011). Due to the low cost and 
ready availability, ultrasonography is the most popular 
technique to detect liver disease. However, ultra-
sonography is highly-operator dependent and liver 
echogenicity can not accurately differentiate hepatic 
fibrosis from steatosis (Bataller and Brenner, 2005). 
Therefore, noninvasive serological biomarkers become 
one of the solutions for complementing the diagnosis of 
liver fibrosis, indicating that the development of reliable 
noninvasive biomarkers for assessing hepatic fibrosis in 
therapeutic purpose is urgent.  
Approximately 70% of the patients infected with heap-
titis C virus (HCV) become chronic carriers (Marcellin, 
1999) and chronic inflammation could lead to fibrosis, 
liver cirrhosis or even hepatocellular carcinoma. Liver 
fibrosis is the process of repair when liver is injured or in 
inflammation (Marcellin, 1999). In liver tissue, hepatic 
stellate cells (HSCs) are the major source of extracellular 
matrix proteins (ECMs) excretion in facing constant 
inflammation and eventually triggers fibrogenesis (Eng 
and Friedman, 2000; Friedman, 2000, 2003; Marcellin, 
1999). Furthermore, cytokines that participate in the 
inflammatory process (Marra, 2002) are secreted into 
blood. For example, the level of interferon gamma 
inducible protein 10 (IP-10), increases in the serum of 
HCV-infected patients, and has significant correlations 
with poor response to anti-viral therapy (Reiberger et al., 
2008). Therefore, serum cytokines may be used as 
biomarkers of hepatic inflammation or fibrosis. 
Currently, many biomarkers have been reported to be 
correlated with liver fibrosis, including alpha-2 
macroglobulin, vitamin D binding protein, apolipoprotein 
AI (Ho et al., 2010), tissue inhibitor of metalloproteinases-
1 (TIMP-1), hyaluronic acid (HA), N-terminal propeptide 
of type III procollagen (PIIINP), and YKL-40 (Bataller and 
Brenner, 2005; Johansen et al., 2000; Poynard et al., 
2002). Moreover, several biomarker panels such as 
FibroTest, Forns index, AST-to-platelet ratio index (APRI) 
and GlycoCirrhoTest have been reported to stage fibrosis 
(Callewaert et al., 2004; Le Calvez et al., 2004; Rossi et 
al., 2003; Thabut et al., 2003). In the past, the discovery 
of serological biomarkers was limited due to the abundant 
amount of albumin and IgG in serum, which would 
decrease the accuracy in analytical experiments. 
Therefore, the low abundant proteins such as cytokines 
in serum have not been analyzed. Regardless of two 
dimension   electrophoresis   (Gangadharan   et al., 2007; 
White et al., 2007) or other existing technologies, 
analyzing proteins at micro- or pico-level quantity in 
serum has been difficult. Using specific antibodies to 





profiling (xMAP) technology may be another solution to 
detect the  low-abundant  serum  proteins.  In  this  study,   
noninvasive serological biomarkers were discovered 
using Bio-Plex suspension array system based on xMAP 
technique. This method provided a broad screening for 
different proteins using specific antibody (Yurkovetsky et 
al., 2007). Due to the high reproducibility of robust assay 
and high precision of immunoassay, we used commercial 
cytokines 27- and 23-panels to search for putative serum 
biomarkers of liver fibrosis. Less total assay time, fewer 
progressive steps and smaller sample volume were 
needed using xMAP compared to conventional enzyme-
linked immunosorbent assay (ELISA). It also provided 
multiple analyses at the same time and had higher 
reproducibility because the result was the mean value 
after multiple readings (Chowdhury et al., 2009; dupont et 
al., 2005; Prabhakar et al., 2002). By this way, com-
parison of 50 cytokines between normal and disease 
group were completed, and candidate biomarkers were 
selected. This study aimed to investigate whether over-
expressed cytokines could be used as serological 




MATERIALS AND METHODS 
 
Serum sample  
 
Serum samples (n = 61) from HCV-infected patients were obtained 
in Cheng Hsin general hospital in Taiwan (approval No. 97016). 
Firstly the blood samples were allowed to clot for 30 min at 4°C and 
then centrifuged at 1400 × g at 4°C. Collected serum was frozen at 
-80°C for store. The patients were diagnosed by a pathologist using 
hepatic biopsy procedure and followed in subsequent histological 
examinations. The serum samples were used to determine the 
stages of hepatic fibrosis according to METAVIR classification, 
including F1, F2, F3 and F4. On the other hand, we analyzed three 
individual HCV-infected samples in every stage of liver fibrosis and 
compared results to three healthy controls; liver biopsy in control 
group was not performed due to ethical issues. 
 
 
Cytokine standard preparation 
 
The cytokine 23-plex panel or 27-plex panel (Bio-Rad) were used in 
this study. Each 128 µL of cytokine stocks were added with 72 µL of 
serum standard diluent and continued to make four-fold serial 
dilution to eight standard samples totally.  
 
 
Flexible multi-analyte profiling  
 
The 25 µL of the serum samples was diluted with 75 µl of the 
appropriate human serum sample diluent (Bio-Rad). We used Bio-
Plex
TM
 Human Cytokine 27-Plex and 23-Plex Panel to search for 
putative biomarkers of hepatic fibrosis in serum. The experiment 
followed the instruction manual described briefly as below. First, 50 
µL of anti-cytokine conjugated beads was incubated with 50 µL of 
diluted standard or sample in each well of a 96-well   filter   plate  at 
room temperature for exactly 1 h on a shaker with 300 rpm. After 
removing the solution and washing, we added 25 µL of detective 
antibody conjugated with biotin to each well and incubate for 30 min 




Table 1. Characteristic of 61 HCV-infected liver fibrosis patients 
  
Characteristic 
Stages of liver fibrosis P value 











BMI 26.0±0.8 23.6±1.1 24.5±0.9 25.8±0.8 NS 
AST (IU/L) 60.5±6.8 111.0±40.9 88.7±11.5 112.5±8.3 NS 
ALT (IU/L) 143.6±18.2 131.1±17.5 141.2±21.9 143.0±13.8 NS 
WBC (1000/µl) 6.5±0.3 5.7±0.3 6.2±0.4 5.0±0.3 0.016 
Plt (1000/µl) 221.6±15.7 189.5±7.1 178.6±13.22 113.9±8.6 <0.001 
 





on a shaker with 200 rpm. Then 50 µL of streptavidin-Phycoerythrin 
 (PE) was added in each well and incubated for 10 min on a shaker. 
Afterward, each well was added with 125 µL of assay buffer and it 
was ready for the measurement. A black was necessary for the 
measurement and all the incubations were performed in dark. 
 
 
Statistical analysis  
 
After fluorescent measurement by Bio-Plex 200 suspension array 
system, we used five-parameter logistic regression algorithms (5PL) 
to calculate the standard curve. This regression is commonly used 
in immunoassays and provides a large range of quantification than 
linear regression analysis. The concentrations of measured 
cytokine were calculated using Bio-Plex manager 4.1 software. The 
p value was calculated using one-way analysis of variance 








A total of 61 patients with chronic hepatitis C were 
enrolled. The stage of liver fibrosis was determined by 
histological findings. The clinical characteristics of the 
samples were investigated by measuring several indi-
cators, including aspartate aminotransferase (AST), 
alanine transaminase (ALT), white blood cells (WBCs), 
and platelet. The conventional indicators of liver function, 
AST and ALT, were not associated with the stage of liver 
fibrosis (Table 1). However, we previously demonstrate 
that AST and ALT increased in thioacetamide-induced 
liver fibrosis animal model as compared to healthy 
controls (Liu et al., 2011). Moreover, the levels of AST (> 
60.5 IU/L) and ALT (> 131.1 IU/L) indeed were higher 
than healthy ones, demonstrating that AST and ALT were 
the markers of liver disease. WBC and platelet were 
decreased in advanced liver fibrosis (both p < 0.05) as 
previously reported (Wai et al., 2003). The APRI index 
was increased from F1 to F4 stage (p < 0.0001, Figure 
1A). Moreover, histology activity index (HAI) score was 
increased with the progression of liver fibrosis (p = 0.003, 
Figure 1B), indicating inflammation was accompanied 
with the progression of liver fibrosis.  
 
 
Discovery of cytokine biomarker of liver fibrosis 
 
To identify the putative cytokine biomarkers of liver 
fibrosis in this study, xMAP was used. A total of 15 serum 
samples from HCV-infected patients’ triplicate in each 
stage of liver fibrosis and healthy controls were analyzed, 
which were selected in accordance with the level of HAI 
index in Figure 1B. Moreover, the samples were collected 
before the patients received any clinical treatment, such 
as anti-viral therapy, and liver transplantation. The total 
protein concentration was equivalent in each stage of the 
serum samples (data not shown). In the xMAP analysis, 
we totally analyzed 50 available cytokines using 
commercial 23- and 27-Plex panel (Bio-Rad). Due to the 
fact that the beads were stained with two different 
fluorescent dyes and formed 100 different types, it 
allowed us to analyze the protein level at the same time. 
After xMAP analysis, we finally found that four cytokines 
were increased gradually in serum from normal controls 
and patients with F1 to F4 stage of liver fibrosis, including 
interferon-α2 (IFN-α2), growth-related oncogene-α (GRO-
α), stem cell factor (SCF), and stromal cell derived factor-
1α (SDF-1α) (Figure 2). Other measured cytokines were 
irregular with the stages of liver fibrosis (data not shown).  
 
 
ROC curves of four serum fibrosis indices 
 
We used receiver operating characteristic (ROC) analysis 
to distinguish normal/F1 from F2 to F4. The area under 
curve (AUC) of serum fibrosis indices in ROC curves are 
shown in Table 2, which demonstrated that these four 
liver fibrosis markers had acceptable discrimination (all > 
0.8, p < 0.05) for diagnosing liver fibrosis. Moreover, 
ROC analysis was also used to determine the   sensitivity 
and 1-specificity of the assay in detecting the severity of 
liver fibrosis. On this account of taking higher sensitivity






Figure 1. APRI and HAI levels in the stages of liver fibrosis. (A) APRI index was used to evaluate the enrolled patients with hepatitis 
C virus-induced liver fibrosis. The result shows that APRI increased gradually from F1 to F4, indicating APRI is a reliable index for 
predicting liver fibrosis. (B) HAI was also performed to measure the necroinflmmatory levels of the tissues with liver fibrosis, which 
demonstrated that HAI increased from F1 to F4, indicating inflammation was accompanied with liver fibrosis. AST, aspartate 




and specificity, the cut-off points of the four indices were 





This study aimed to widely screen serum cytokines and 
evaluate their relationship with liver fibrosis using xMAP. 
Furthermore, four cytokines including IFN-α2, GRO-α, 
SCF and SDF-1α were identified to elevate in serum in 
parallel with severity of fibrosis in chronic hepatitis C 
patients. In addition, the concentrations of these 
cytokines were measured as references to predict the 
stage of liver fibrosis in patients with chronic hepatitis C.  
Clinically, ELISA is a useful tool for determining serum 
antibody concentrations and is usually performed for 
disease diagnosis. However, Thierry’s group reported 
that the results obtained by xMAP assay were not 
consistant with the data derived from ELISAs and a 
constant conversion factor (Reijn et al., 2007). Therefore, 
the absolute concentrations of the four candidate proteins 
may be different between these two assays and specific 
reference value must be defined for each type of analysis 
(Elshal and McCoy, 2006; Ray et al., 2005). For clinical 
application, it is necessary to measure the reference 
values for ELISA or xMAP assay; the later one can 
measure multi-markers at once and could be used to 
replace conventional ELISA assay in the future.  
To our knowledge, xMAP assay was used to 
simultaneously evaluate the cytokine expressions in 
HCV-infected patients after anti-viral treatment (Wan et 
al., 2009). In this study, we used xMAP to evaluate the 50 
kinds of cytokines in HCV-infected liver fibrosis. For the 
searched results, the level of SDF-1α was found to be 
increased in liver disease such as fibrosis or cirrhosis 
(Horani et al., 2007; Itoh et al., 1994; Panasiuk et al., 
2007; Radaeva et al., 2006; Wald et al., 2004; Wald et 
al., 2007). However, IFN-α2 and GRO-α were reported to 
be associated with the stage of liver fibrosis for the first 
time. IFN-α2 was prioritized to treat chronic hepatitis B 
and C in many clinical trials (Buti and Esteban, 2005; 
Cooksley, 2005). Furthermore, interferon plus ribavirin 
has become the standard of care for the treatment of 
chronic hepatitis C. On the other hand, GRO-α (also 
called CXCL1), a chemokine of C-X-C family, significantly 
increased in liver tissue of alcoholic hepatitis (Maltby et 
al., 1996). To the best of our knowledge, this is the first 
report that IFN-α2, SCF and GRO-α increase in liver 
fibrosis, thus could be used as putative biomarkers for 
predicting the severity of liver fibrosis. In particular, GRO-
α, expressed by macrophages, neutrophils and epithelial 
cells, with neutrophil chemoattractant activity involved in 
the accumulation of neutrophils, and thus mediated liver 
injury and inflammation (Ramaiah and Jaeschke, 2007). 
Different cytokines are secreted during inflammatory 
process under many causes of liver injury such as 
ethanol abuse, viral infection, cholestasis or metabolic 
syndrome; these four cytokines were confirmed to be 
specifically associated with the stage of liver fibrosis in 
histological examination in this study. However, further 
studies are still needed to reveal the role of the four 
discovered cytokines in the progression of liver fibrosis. 
In this study, we also found that other cytokines, including 
interleukin  (IL)-2ra, IL-3, IL-12, IL-16, IL-18, Cutaneous T






Figure 2. The overexpressed cytokine biomarkers of HCV-infected liver fibrosis. Totally we discovered four candidate biomarkers with 
increase trend from normal to advanced hepatic fibrosis by using box-whisker plot, including IFN-α2, SCF, GRO-α and SDF-1α. There 
were 15 samples analyzed, including the samples from normal controls (n=3), F1 (n=3), F2 (n=3), F3 (n=3) to F4 (n=3). IFN-α2, 




cell-attracting chemokine (CTACK), hepatocyte growth 
factor (HGF), intercellular adhesion molecule-1 (ICAM-1), 
leukemia inhibitory factor (LIF), macrophage colony-
stimulating factor (M-CSF), tumor necrosis factor-related 
apoptosis inducing ligand (TRAIL), vascular cell adhesion 
molecule-1 (VCAM-1), IP-10,  increased  in HCV-infected  
liver fibrosis (F2 to F4) compared to normal or early stage 
(data not shown). In which, the elevated IL-18 was 
consistent with the previous study which revealed that 
higher serum level of IL-18 in HCV infection (Chattergoon 
et al., 2011). Unfortunately, the level of IL-18 did not 
gradually increase with the stages of liver fibrosis 
(p>0.05, data not shown). Moreover, the elevated IP-10 
level was consistent with the study reported previously for 
predicting the response of HCV viral load, the hepatic 
inflammatory activity, and fibrotic stage (Reiberger et al., 
2008). Those cytokines seem to associate with the HCV 
infection or hepatic inflammation. Take together, 
serological biomarkers are one of the solutions to 
diagnose liver fibrosis in hepatitis C patients in order to 
decrease the use of invasive liver biopsy. Observably, the 
cytokines found in this study are  in   low   abundance (<1  




Table 2. ROC curve of the four liver fibrosis indexes. 
 
Index AUC Cut-off point (pg/ml) Sensitivity 1-Specificity p 
IFN-α2 0.907 56.30 0.778 0.167 0.010 
GRO-α 0.889 46.45 0.667 0.167 0.013 
SCF 0.907 28.95 0.778 0.167 0.010 
SDF-1α 0.889 152.65 0.667 0.167 0.013 
 





ng/mL). Due to the inference from highly abundant 
albumin    and   IgG   in serum,  the   detection   of   some 
valuable yet less abundant proteins like cytokines that 
present in pico or micro levels requires highly sensitive 
technique. In this study, we found four putative bio-
markers of liver fibrosis, including IFN-α2, SCF, GRO-α 
and SDF-1α, using flexible multi-analyte profiling and 
measured the  protein  concentrations  in  each  stage  of 
liver fibrosis.  
In conclusion, this study was to assess the association 
of cytokines with liver fibrosis using xMAP. Four 
cytokines, IFN-α2, GRO-α, SCF and SDF-1α, were found 
to be increased in serum in parallel with the severity of 
liver fibrosis in patients with chronic hepatitis C, sug-
gesting they could be used as markers for predicting the 
severity of liver fibrosis and reduce the usage of invasive 
liver biopsy in clinical practice. However, the role of these 
cytokines in the progression of liver fibrosis needs further 
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